GENOME RESEARCH LIMITED

Active Saffron Walden

Research and experimental development on biotechnology

1,301 employees website.com
Property, infrastructure and construction Commercial real estate Research and experimental development on biotechnology
G

GENOME RESEARCH LIMITED

Research and experimental development on biotechnology

Founded 20 Aug 1992 Active Saffron Walden, England 1,301 employees website.com
Property, infrastructure and construction Commercial real estate Research and experimental development on biotechnology
Accounts Submitted 3 Mar 2026 Next due 30 Jun 2026 2 months remaining
Confirmation Submitted 23 Jun 2025 Next due 7 Jul 2026 2 months remaining
Net assets £274M £3M 2025 year on year
Total assets £317M £41M 2025 year on year
Total Liabilities £43M £44M 2025 year on year
Charges 1
1 satisfied

Contact & Details

Contact

Registered Address

Wellcome Sanger Institute Wellcome Genome Campus Hinxton Saffron Walden CB10 1SA England

Telephone

0800 000 0000

Email

info@example.com

Website

www.example.com

Full company profile for GENOME RESEARCH LIMITED (02742969), an active property, infrastructure and construction company based in Saffron Walden, England. Incorporated 20 Aug 1992. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2025
Type Total Exemption Full
Next accounts 31 December 2026
Due by 30 September 2027 9 months

Balance Sheet & P&L (2014–2025)

Cash in Bank

£16.68M

Increased by £1.32M (+9%)

Net Assets

£273.70M

Increased by £3.46M (+1%)

Total Liabilities

£43.00M

Decreased by £44.12M (-51%)

Turnover

£180.35M

Increased by £3.00M (+2%)

Employees

1301

Increased by 5 (+0%)

Debt Ratio

14%

Decreased by 10 (-42%)

Financial History

Revenue, profit, EBITDA and key financial figures

2025
Dec Year End
2024
Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Grants 16

Investors (0)

No investor information available

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (1)

The Wellcome Trust Limited
100.0%

Persons with Significant Control

Persons with Significant Control (1)

1 Active
Notified 6 Apr 2016
Nature of Control
  • Voting Rights 75 To 100 Percent,significant Influence Or Control As Trust

Group Structure

Group Structure

GENOME RESEARCH LIMITED Current Company
BASE RX LIMITED united kingdom
HINXTON HALL LIMITED united kingdom

Charges

Charges

1 satisfied

Properties

Properties

1 leasehold 1 total
AddressTenurePrice PaidDate Added
Wellcome Trust Genome Campus, Hinxton, Saffron Walden (CB10 1SD) SOUTH CAMBRIDGESHIRE
Leasehold-18 Mar 2013
Wellcome Trust Genome Campus, Hinxton, Saffron Walden (CB10 1SD)
Leasehold
Added 18 Mar 2013
District SOUTH CAMBRIDGESHIRE

Documents

Company Filings

DateCategoryDescriptionDocument
9 Apr 2026OfficersTermination of Michael Dunn as director on 2026-03-25
1 Apr 2026OfficersTermination of Karen Chadwick as director on 2026-03-31
1 Apr 2026OfficersAppointment of Mr Nick Skinner as director on 2026-04-01
3 Mar 2026AccountsAnnual accounts made up to 2025-09-30
23 Jun 2025Confirmation StatementConfirmation statement made on 2025-06-23 with no updates
9 Apr 2026 Officers

Termination of Michael Dunn as director on 2026-03-25

1 Apr 2026 Officers

Termination of Karen Chadwick as director on 2026-03-31

1 Apr 2026 Officers

Appointment of Mr Nick Skinner as director on 2026-04-01

3 Mar 2026 Accounts

Annual accounts made up to 2025-09-30

23 Jun 2025 Confirmation Statement

Confirmation statement made on 2025-06-23 with no updates

Recent Activity

Latest Activity

Termination of Michael Dunn as director on 2026-03-25

2 weeks ago on 9 Apr 2026

Termination of Karen Chadwick as director on 2026-03-31

3 weeks ago on 1 Apr 2026

Appointment of Mr Nick Skinner as director on 2026-04-01

3 weeks ago on 1 Apr 2026

Annual accounts made up to 2025-09-30

1 months ago on 3 Mar 2026

Confirmation statement made on 2025-06-23 with no updates

10 months ago on 23 Jun 2025